



Healthcare

The healthcare industry around the world is intricate and evolving. Healthcare laws and regulations affect all companies at some level. The healthcare industry is among the most highly regulated in the world, and all employers must comply with the medical privacy protections and healthcare benefits afforded their employees. Multinational companies must navigate sometimes quite divergent payment and reimbursement regimes and the pharmaceutical and medical device approval rules of multiple national governments, as well as regional and international requirements. Healthcare providers are subject to the licensing and oversight rules of every jurisdiction in which they do business.

RELATED SECTORS

- Digital Health

Our lawyers represent healthcare clients all around the world. We live and work where our clients live and work. And we work together across our offices throughout Asia Pacific, Europe, the Middle East and the United States, combining global strategy with local implementation.

We counsel the healthcare industry in these areas:

- Antitrust and competition
- Project finance
- Healthcare transactional
- Healthcare fraud and compliance
- Health insurance and managed care
- Healthcare regulatory
- Healthcare technology
- Employment
- Payment reimbursement disputes
- Pensions
- Personal injury and product liability litigation
- Privacy
- Professional liability and litigation
- Restructuring

Publikationen

Your clinical decision support software may now be regulated by FDA as a medical device

30 September 2022

A comprehensive overview of FDA's regulatory approach to Clinical Decision Support software.

Bioeconomy Executive Order: A whole-of-government approach to advancing biotechnology and biomanufacturing

26 September 2022

The EO signals the Biden Administration's commitment to US leadership in biotechnology and biomanufacturing.

Spies among us: State-sponsored actors want to steal your sensitive information

21 September 2022

INTELLECTUAL PROPERTY AND TECHNOLOGY NEWS

The joint statement is an implicit admission by both governments that they can no longer protect private businesses from state-sponsored intellectual property theft.

Karyopharm highlights practical considerations for life sciences companies' disclosures about products in development

20 September 2022

The decision provides some practical guidance for life sciences companies' decisions regarding statements about products in development.

Preemption in the abortion context – recent cases shed light on limits of federal law to supersede state restrictions

20 September 2022

The implications of these preemption issues on certain stakeholders are not to be understated.

AI risk assessments: Future-proofing your innovation when rules can change mid-game

15 September 2022

AT THE INTERSECTION OF SCIENCE AND LAW PODCAST SERIES

Danny Tobey is joined by Aviva Wein to discuss how medical device and pharmaceutical companies are future-proofing their innovations in artificial intelligence as new regulations and risks arise.

As the public health emergency continues, OIG and CMS issue documents impacting telehealth providers

September 13, 2022

Telehealth providers should stand ready to revise current practices to align with federal regulations and enforcement priorities.

Hear ye, hear ye! FDA finalizes OTC hearing aids rule and issues updated guidance on personal sound amplification products

6 September 2022

A paradigm shift for the hearing aid industry and patients.

Inflation Reduction Act makes substantial changes to federal healthcare laws

19 August 2022

The topline on how this law impacts health policy.

Inside the Inflation Reduction Act

19 August 2022

A look at the business-critical aspects of this sweeping, extraordinary legislation and its implications for clean energy projects, electric vehicle development, corporate taxes, healthcare, and environmental policy.

Infectious diseases in the workplace: What employers should know about monkeypox and COVID-19

15 August 2022

Employers may consider leveraging lessons learned from the COVID-19 pandemic to keep workers safe.

FDA issues draft guidance on conducting remote regulatory assessments

1 August 2022

A clear sign that remote regulatory assessments are here to stay.

Israel Group News July 2022

28 July 2022

ISRAEL GROUP NEWS

In this issue, our global activities, latest publications, recent events and more.

Fading into the sunset: The last of the Sunset Rule (for now)

27 July 2022

HHS concluded the Sunset Rule was inconsistent with the department's statutory obligations and its mission to promote and protect the public health.

HIPAA guidance on disclosures relating to reproductive healthcare: Risk mitigation and strategies

26 July 2022

The guidance reminds covered entities and their business associates that, absent an individual's authorization, they may use and disclose personal health information only as expressly permitted or required by HIPAA.

US Department of Justice and HHS-OIG target telemedicine companies, issuing companion enforcement action and Special Fraud Alert

26 July 2022

OIG and DOJ are focusing on instances where there is no medical necessity or where companies improperly incentivize practitioners.

FDA issues final guidance on patient labeling for drugs and biologics

25 July 2022

FDA's final guidance provides recommendations to maximize the clear presentation of IFU instructions and enhance patient understanding.

FDA Regulatory News and Trends

15 July 2022

[FDA REGULATORY NEWS AND TRENDS](#)

FDA announces a new action plan for rare neurodegenerative diseases.

Coming EU legislation will change the AI regulatory environment for healthcare technology and life sciences companies

11 July 2022

[AI OUTLOOK](#)

Organizations must consider the extraterritorial reach of the regulations and how they will affect the way business is carried out.

A step forward in the FY2023 appropriations process: Key proposals the life sciences sector should watch

8 July 2022

True to form, the House of Representatives is off to a fast start.

The rise of global telehealth

30 June 2022

[AT THE INTERSECTION OF SCIENCE AND LAW PODCAST SERIES](#)

Partners Kristi Kung and Greg Bodulovic discuss the rise of telehealth amid the COVID-19 pandemic, as well as advancements in

technology aiming to address disparate access to healthcare globally.

Coming soon: a national security screening mechanism for outbound investments

28 June 2022

The US would not be alone in regulating outbound investment.

Former BIO CEO Jim Greenwood: 1 million dead, \$16 trillion in losses is our wake-up call on pandemic preparedness

7 June 2022

While biological events may be inevitable, their level of impact on our country is not.

FDA premarket approval and the use of “FDA Approved” claims

17 May 2022

When do products, facilities, labels, and claims require Formal Premarket Approval, and when do they not?

Israel Group News April 2022

28 April 2022

ISRAEL GROUP NEWS

In this issue, our global activities, latest publications, recent events and more.

COVID-19 two years in: Four key trends in the state of compliance

17 March 2022

PRACTICAL COMPLIANCE

What it means to be compliant today is not what it meant in March 2020.

The beginning of the end: FDA details roadmap to terminating COVID-19 EUAs and enforcement policies for medical devices, PPE

2 March 2022

The webinar sought to prepare stakeholders for the upcoming transition back to normal operations by describing its expectations for the industry over the 180-day transition period.

Medicare audit? CMS expands ability to revoke for non-compliant billing

14 February 2022

These broad revisions provide CMS with greater revocation authority.

Telehealth's impact on low-income communities

24 January 2022

[AT THE INTERSECTION OF SCIENCE AND LAW PODCAST SERIES](#)

Shared from our Beyond the Curve podcast series

Ray Williams and Kirsten Axelsen are joined by Dr. Benson Hsu of the University of South Dakota Sanford School of Medicine for a frank discussion on disparities to engaging with telehealth and ways to better serve low income communities. Originally recorded on March 3, 2021.

Israel Group News January 2022

24 January 2022

[ISRAEL GROUP NEWS](#)

In this issue, our global activities, latest publications, recent events and more.

2022 – a busy year for privacy legislation has already started

12 January 2022

Biometric privacy, cybersecurity standards and consumer protection are among the subjects of the bills.

Supporting the health of your health system: 2022

3 January 2022

Helping you tend to healthcare system wellness throughout the business life cycle.

The crossroad of science and law

16 December 2021

[AT THE INTERSECTION OF SCIENCE AND LAW PODCAST SERIES](#)

Lucas Przymusinski and Raymond Williams are joined by Michael King, Vice President and Associate General Counsel at Jazz Pharmaceuticals, to discuss the benefits of medical and science backgrounds when litigating matters for pharmaceutical and medical device companies.

Third Circuit deepens circuit split on government's ability to dismiss qui tam complaints over relator's objection

11 November 2021

When is the government entitled to dismiss a relator's complaint over the relator's objection? The split among the circuits deepens.

Takeaways from the new USPS rule prohibiting the mailing of vape products

29 October 2021

The Final Rule clarified that hemp vape products are included within the definition of ENDS, and are thus nonmailable.

Food and Beverage News and Trends

28 October 2021

[FOOD AND BEVERAGE NEWS AND TRENDS](#)

FDA announces initiative to improve children's diets; massive study finds using salt substitute is low-cost way to reduce stroke risk; onion recall expands.

Israel Group News October 2021

25 October 2021

[ISRAEL GROUP NEWS](#)

In this issue, our global activities, latest publications, recent events and more.

Understanding AI and its use in drug discovery

6 October 2021

[AT THE INTERSECTION OF SCIENCE AND LAW PODCAST SERIES](#)

DLA Piper partners Ellen Scordino and Susan Krumplitsch are joined by Duane Valz, General Counsel of Insitro, to discuss how machine learning is being used to generate and leverage data for the development of better medicines.

FTC's Policy Statement on breach notifications in mobile health apps: a new, broad approach that may face legal challenge

27 September 2021

The Policy Statement highlights the FTC's intention to step up enforcement consistent with these broad new interpretations.

The global landscape of data privacy: Important points about new laws in three key jurisdictions

21 September 2021

[PRACTICAL COMPLIANCE](#)

New data privacy requirements in three important jurisdictions – the European Union, China, and Brazil – with an emphasis on action steps for compliance officers.

The Hidden Cost of Price Control Policies with Kirsten Axelsen

15 September 2021

An interview with Kirsten Axelsen about what would change in biopharma if price controls were implemented.

President Biden announces new vaccination requirements – what private employers and federal contractors need to know

14 September 2021

Employers already struggling with a puzzling array of compliance challenges aimed at combating COVID-19 now face additional vaccination and testing requirements.

Split Seventh Circuit lowers the bar for pleading a False Claims Act violation

14 September 2021

Defendants are again at risk for False Claims Act liability for what appear to be mere breaches of contract or technical regulatory violations.

mRNA Technology: A New Approach to Therapeutics

8 September 2021

[AT THE INTERSECTION OF SCIENCE AND LAW PODCAST SERIES](#)

Dr. Lisa Haile talks with Dr. Kathy Fernando about the study of mRNA and how COVID-19 catalyzed its advancement.

Seventh Circuit adopts objective reasonableness standard for False Claims Act liability

1 September 2021

Key details and takeaways.

Cybersecurity considerations for executives and boards of directors: How recent cyberattack trends and developments inform strategies for reducing cyber-risk

23 August 2021

We review recent trends and costs associated with cyberattacks and analyze how organizations can implement strategies for reducing cyber-risk.

Israel Group News August 2021

16 August 2021

[ISRAEL GROUP NEWS](#)

In this issue, our global activities, latest publications, recent events and more.

New workplace protections for medical cannabis patients in Puerto Rico

12 August 2021

The new law creates a new protected category under Puerto Rico antidiscrimination laws.

SCOTUS upholds the ACA: Next steps for employers

8 July 2021

All ACA provisions regarding the employer mandate for large employers continue in effect; in addition, ACA patient protection provisions

have been expanded by the Consolidated Appropriations Act, 2021.

Global corporate benchmarking group seeks inputs on corporate human rights standards

22 June 2021

Comments are requested by June 25, 2021.

Whatever your sector, ransomware attacks are changing how to think about platform security risk: Action steps

14 June 2021

In an increasingly digitized economy, creating awareness of platform security risks is critical.

FDA solicits public comment on adding list of device materials to certain medical device labels

26 May 2021

The proposed change would apply to all medical devices that may be in contact with a patient long term.

Israel Group News May 2021

1 May 2021

[ISRAEL GROUP NEWS](#)

In this issue, our global activities, latest publications, recent events and more.

FDA warning letters: More warnings and closer scrutiny of COVID-19 and vaping products

26 April 2021

A large percentage of warning letters concern adulterated, unapproved or misbranded products related to COVID-19, and e-cigarette companies continue to be in the agency's crosshairs for selling unapproved products.

eSignature and ePayment News and Trends

2 April 2021

[ESIGNATURE AND EPAYMENT NEWS AND TRENDS](#)

Continuing the digital transformation into 2021.

Top employee benefits issues to watch

31 March 2021

The top 10 issues likely to impact plan sponsors in 2021 and beyond.

The Drivers of SPACs and Why They are Here to Stay

4 March 2021

HEALTHCARE Q&A SERIES

At the DLA Piper 2021 Healthcare Leadership Conference, both Josh and Jeff will join a panel to discuss the latest developments in capital markets for healthcare companies including SPACs.

Making Compliance Part of Your Business DNA

2 March 2021

HEALTHCARE Q&A SERIES

At the DLA Piper 2021 Healthcare Leadership Conference, Charles will participate in the panel, *What is an effective compliance program*. This session will explore the shift in the federal government's approach to compliance program effectiveness and how new trends will impact organizational and enforcement efforts in the future.

Legislators and regulators continue to support digital transformation

26 February 2021

Endorsing the movement towards digital transformation.

eSignature and ePayment News and Trends

26 February 2021

ESIGNATURE AND EPAYMENT NEWS AND TRENDS

How legislatures and regulators endorse the movement towards digital transformation.

Expectations for white collar enforcement under the Biden Administration

18 February 2021

Six key areas where the Biden Administration may focus its enforcement efforts.

Israel Group News January 2021

19 January 2021

ISRAEL GROUP NEWS

In this issue, our global activities, latest publications, recent events and more.

No Surprises Act creates new model for commercial payors and providers

7 January 2021

The act contains consumer protection and transparency requirements that may fundamentally change health payor and provider operations.

Supporting the health of your health system

4 January 2021

Helping you tend to healthcare system wellness throughout the business life cycle.

Senate approves bill eliminating antitrust exemption for health insurers

29 December 2020

New antitrust compliance challenges for the health insurance industry.

The EEOC breaks its silence on the COVID-19 vaccine

22 December 2020

Some of the most important questions answered by the EEOC's guidance.

When a threat actor strikes: Legal considerations and challenges in a ransomware attack

21 December 2020

Evidence suggests that having employees working remotely significantly increases the risk of a successful ransomware attack.

Silver linings for FCA defendants in new HHS Working Group

11 December 2020

The US Department of Health and Human Services is launching the Working Group to better protect taxpayer funds and deter "would-be fraudsters."

FDA seeks feedback on industry best practices for medical device cybersecurity communications

9 December 2020

The agency emphasizes the evolving responsibility of medical device manufacturers to promptly, clearly communicate cybersecurity issues to patients and healthcare providers.

Practical Compliance

8 December 2020

PRACTICAL COMPLIANCE

Q4 2020: Spotlight on real estate COVID-19 compliance.

CMS, OIG finalize Stark and AKS overhaul – paving the way for value-based care

25 November 2020

We highlight some of the most important ways in which HHS followed through on its ideas from 2019, as well as the instances where they pivoted in reaction to public comments.

HHS-OIG issues alert warning pharmaceutical and device manufacturers about the kickback risks of speaker programs

24 November 2020

Key details and takeaways.

The US Hemp Production Handbook

4 November 2020

A concise, high-level overview for businesses that are currently or are considering operating in this growing market.

Israel Group News October 2020

7 October 2020

ISRAEL GROUP NEWS

In this issue, our global activities, latest publications, recent events and more.

Avoid misclassification quagmires by understanding differences between contractors and employees

23 APR 2018

Classification missteps can translate to significant legal and economic risk for businesses, and workers who are not properly classified also face negative consequences.

Precarious steps: patent eligibility for healthcare IT

26 SEP 2016

Three recent Federal Circuit decisions, along with new updates from the USPTO, offer guidance on which steps to take in patenting healthcare IT-related inventions.

Stop them in their tracks: key points in seeking a preliminary injunction against medical device infringers

22 SEP 2016

Three considerations to bear in mind when bringing or defending a preliminary injunction motion in a medical device infringement case.

Is your cybersecurity upgrade FDA reportable?

28 SEP 2016

Draft guidance lends insight into the way the FDA may apply existing postmarket regulatory requirements to evolving cybersecurity-related technological issues.

Cybersecurity: past is prologue

29 MAR 2016

During 2016, we will likely see another increase in cyberattacks, and we will see cybersecurity being taken more seriously by its potential victims.

Supreme Court Corner: Q1 2016

29 MAR 2016

Two cases to watch.

Intellectual Property and Technology News (United States), Issue 23, Q3 2014

10 SEP 2014

[INTELLECTUAL PROPERTY AND TECHNOLOGY NEWS](#)

Our Intellectual Property and Technology News reports on worldwide developments in IP and technology law, offering perspectives, analysis and visionary ideas.

Substitution allowed? State biosimilars laws are evolving

10 SEP 2014

Biosimilar products have not yet reached the US market, but debates on the laws and regulations that will govern them have been raging for some time

Supreme Court Corner - Q3 2014

10 SEP 2014

A review of cases relevant to IPT decided or argued before the Court during Q3

Public-Private Partnerships in Puerto Rico

21 MAR 2017

For those considering participating in P3s in Puerto Rico, this handbook summarizes the applicable legal framework and discusses why Puerto Rico is a favorable jurisdiction for entering into P3s.

Universal Health Services: contractors take note – Supreme Court approves implied certification theory of False Claims Act liability

22 JUN 2016

The Court's recognition of "implied certification" theory resolves a circuit split in favor of a more expansive view of the Act.

DLA Piper's Guide to Restructuring Issues for Not-For-Profit Companies and Their Directors

29 OCT 2015

Understanding the financial challenges in preserving an NFP and its mission

Wellness innovators take note: FDA reveals risk-based approaches to the regulation of health IT and mobile medical apps

2 FEB 2015

With these draft guidance documents, FDA indicates it will not take enforcement action in connection with low-risk general wellness products and establishes a new risk-based approach to medical device accessories

FDA's new menu labeling and vending machine requirements: 10 key answers for food businesses

2 DEC 2014

The new requirements apply nationwide and preempt existing state laws

Big or small, it's all hardball: merger enforcement actions *below* the HSR threshold - top ten tips in non-reportable transactions

23 JUN 2014

No anti-competitive deal is immune from challenge, even if it is small - 10 important points to keep in mind in M&A transactions

First Lady and nutrition: USDA and FDA propose sweeping food labeling and marketing regulations

27 FEB 2014

Today, First Lady Michelle Obama and the Food and Drug Administration released two long-awaited proposed regulations that would for the first time in 20 years make significant changes to the nutrition information found on food and dietary supplement labels.

Offering healthcare solutions at consumers' fingertips? What you should know about FDA regulation of mobile medical apps

10 OCT 2013

Food safety from farm to fork: FDA publishes proposed rules aiming to ensure the safety and security of the food supply

24 JAN 2013

The proposed rules lay the foundation of the prevention-based, modern food safety system envisioned in the FSMA and have wide-ranging effects on many industries, including every link in the global food supply chain.

Revenue pressure climbs for skilled nursing facilities – what does this mean for healthcare REITs?

3 JUN 2015

Healthcare REITs must be mindful of the challenges they may face due to changes in the healthcare environment

SEMINARE UND VERANSTALTUNGEN

Vergangene

2022 Health Datapalooza and National Health Policy Conference

5 April 2022 | 10:45 ET

Webseminare

OSHA's new vaccination and testing ETS: Key requirements and action steps for employers

12 November 2021 | 12:00 - 1:00 EST

Webinar

US employment law update

12 October 2021 | 1:00 – 2:00 ET

Webinar

False Claims and *Qui Tam* Summit for Life Sciences and Healthcare

24 September 2021

Webseminare

The FCA and nursing homes: A target before and after the pandemic

24 March 2021

Webseminare

2021 Healthcare Leadership Conference: Day 4 - Path to restructuring and recovery

11 March 2021 | 12:00 PM - 3:30 PM ET

[2021 HEALTHCARE LEADERSHIP CONFERENCE](#)

2021 Healthcare Leadership Conference: Day 3 - Washington roundtable

10 March 2021 | 12:00 PM - 3:30 PM ET

[2021 HEALTHCARE LEADERSHIP CONFERENCE](#)

2021 Healthcare Leadership Conference: Day 2 - Unlocking innovation and collaboration through digital health and technology

9 March 2021 | 12:00 PM - 3:30 PM ET

[2021 HEALTHCARE LEADERSHIP CONFERENCE](#)

2021 Healthcare Leadership Conference: Day 1 - The dealmakers, the visionaries and the advocates

8 March 2021 | 12:00 PM - 3:30 PM ET

[2021 HEALTHCARE LEADERSHIP CONFERENCE](#)

The changing business and legal landscape: Key considerations for companies in 2021

5 March 2021 | 1:00 – 2:30 ET

Webinar

Communication and information sharing in support of healthcare for vulnerable populations

22 February 2021

Webseminare

Building a vaccination plan: Key considerations for businesses

18 February 2021 | 9:00 - 10:00 PT

Webinar

How technology is impacting healthcare delivery in a COVID-19 world

13 January 2021 | 1:00 - 2:00 EST

Webinar

The US Election and the Race for a Vaccine: A Roundtable Discussion with Gregory Zuckerman

21 December 2020

Webinar

2020 BioHealth Capital Region Virtual Forum

19 October 2020 | 4:30 - 5:00 EDT
Webseminare

BRG Healthcare Restructuring Conference

12-13 October 2020
New York

NEWS

DLA Piper advises Brookline Capital Acquisition Corp. in the closing of its business combination with Apexigen, Inc.

2 August 2022

DLA Piper advised Brookline Capital Acquisition Corp., a special purpose acquisition company, in the closing of its business combination with Apexigen, Inc., a clinical-stage biopharmaceutical company. The combined, publicly traded company will operate under the name Apexigen, and its common stock commenced trading on the Nasdaq Capital Market on August 1, 2022 under the ticker symbol "APGN."

DLA Piper lawyers and practices ranked in latest edition of *The Legal 500*

15 June 2022

DLA Piper announced today that the firm received 52 firm rankings and 273 lawyers were featured in *The Legal 500 United States 2022* guide.

DLA Piper partner Jessica Wilson named a *Law360* Life Sciences Rising Star

14 June 2022

DLA Piper is pleased to announce that partner Jessica Wilson has been named a 2022 *Law360* Life Sciences Rising Star.

DLA Piper continues expansion of its Regulatory and Government Affairs practice with David Kopans in Washington, DC

6 May 2022

DLA Piper has added nationally regarded healthcare regulatory partner David Kopans in its Washington, DC office.

Bethany Hills joins DLA Piper's FDA Regulatory practice in New York

3 May 2022

DLA Piper continues the growth of its FDA Regulatory group with the arrival of Bethany Hills as a partner in the firm's New York office. Hills will join as vice chair of the FDA practice, working with co-chairs Geoff Levitt and Stefanie Fogel to support their rapid expansion of DLA Piper's FDA regulatory capabilities.

DLA Piper named a top three law firm for private equity deal volume by *PitchBook*

8 March 2022

DLA Piper is pleased to announce that the firm ranked among the top three most active law firms for global private equity deal volume in the past year, according to *PitchBook's* 2021 global league tables report.

DLA Piper advises mPulse Mobile in growth investment from PSG

20 January 2022

DLA Piper represented mPulse Mobile, a leader in conversational AI and digital engagement solutions for the healthcare industry, in a growth investment from PSG, a leading growth equity firm partnering with middle-market software and technology-enabled services companies.

Christopher Halliday joins DLA Piper's Patent Prosecution practice and Life Sciences sector in Philadelphia

18 January 2022

DLA Piper announced today that Christopher Halliday has joined the firm's Patent Prosecution practice and Life Sciences sector as a partner in Philadelphia.

DLA Piper advises Pack4U in its acquisition of Catalyst Healthcare

18 January 2022

DLA Piper represented Pack4U, a connected health services company, in its acquisition of leading pharmacy technology company Catalyst Healthcare.

DLA Piper joins with Duke, Mayo Clinic, UC Berkeley to launch innovative AI collaboration

21 December 2021

DLA Piper has joined with the Duke Institute for Health Innovation, the Mayo Clinic and UC Berkeley, among others, to launch an innovative collaboration designed to build an understanding of the AI software market and allow for its safe and responsible deployment, including of machine learning algorithms.

Campos Mello Advogados announces four new partners

8 December 2021

DLA Piper announced today the addition of four new partners at Campos Mello Advogados (CMA), which has a cooperation agreement with DLA Piper.

DLA Piper partners Jeff Baglio and Erin Gibson named to *San Diego Business Journal's* 2021 Leaders in Law list

15 November 2021

DLA Piper is pleased to announce that partners Jeff Baglio and Erin Gibson have been named to the *San Diego Business Journal's* 2021 Leaders in Law list.

Ardith Bronson, Isabel De Obaldia and Rebecca Jones McKnight named to The American Lawyer's list of 2021 South Trailblazers

4 October 2021

DLA Piper is pleased to announce that Ardith Bronson, Irma Isabel De Obaldia and Rebecca Jones McKnight have been named to *The American Lawyer's* inaugural list of South Trailblazers. The list recognizes professionals in the South "who have moved the needle in the legal industry."

DLA Piper partner Jeff Baglio named a 2021 BTI M&A Client Service All-Star

9 September 2021

DLA Piper is pleased to announce that BTI Consulting Group has recognized partner Jeff Baglio for providing superior service to clients in its 2021 BTI M&A Client Service All-Star report.

DLA Piper achieves appellate victory for AMN Healthcare in antitrust lawsuit

24 August 2021

DLA Piper recently won a significant appellate victory on behalf of AMN Healthcare defeating a lawsuit seeking more than US\$50 million in damages that alleged violations of federal and state antitrust laws.

Deborah Samenow joins DLA Piper's Healthcare sector in Washington, DC

9 August 2021

DLA Piper announced today that Deborah Samenow has joined the firm's Litigation and Regulatory practice and Healthcare sector as of counsel based in Washington, DC.

DLA Piper advises underwriters of MaxCyte's upsized US IPO

30 July 2021

DLA Piper represented Cowen and Company, LLC, Stifel, Nicolaus & Company, Incorporated and William Blair & Company, L.L.C., as underwriters in the initial US public offering of 13,500,000 shares of common stock of MaxCyte, Inc. (Nasdaq: MXCT) (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies, at an initial offering price of US\$13.00 per share.

DLA Piper recognized as one of the "Most Recommended Law Firms" by BTI Consulting Group

26 July 2021

Due to its ability to "exceed client expectations and consistently demonstrate deep business understanding," DLA Piper is pleased to announce that it has been named one of the 11 Most Recommended Law Firms by BTI Consulting Group for 2021.

DLA Piper advises Abry Partners in US\$400 million sale of Sentry Data Systems

16 July 2021

DLA Piper represented private equity investment firm Abry Partners in its US\$400 million sale of Sentry Data Systems, Inc.

DLA Piper advises Lionheart Acquisition Corp. II in US\$32.6 billion SPAC deal with MSP Recovery

13 July 2021

DLA Piper represented special purpose acquisition company (SPAC) Lionheart Acquisition Corp. II. in its agreement to merge with MSP Recovery LLC.

DLA Piper advises FastMed in its acquisition of CareSpot and MedPost Urgent Care

12 July 2021

DLA Piper represented FastMed in its recent acquisition of Tenet Healthcare's urgent care platform, which includes 87 CareSpot and MedPost clinics in Arizona, California, Florida and Texas.

DLA Piper advises emocha Health in US\$6.2 million Series A financing

7 July 2021

DLA Piper represented emocha Health in its recently completed US\$6.2 million Series A financing.

DLA Piper lawyers and practices ranked in latest edition of *The Legal 500*

17 June 2021

DLA Piper announced today that the firm received 42 individual lawyer rankings and 49 firm rankings in *The Legal 500 United States 2021* guide.

DLA Piper advises CareMax in business combination with Deerfield Healthcare Technology Acquisitions Corp.

18 June 2021

DLA Piper represented CareMax Medical Group, L.L.C. in its business combination, along with IMC Medical Group Holdings LLC, with special purpose acquisition company Deerfield Healthcare Technology Acquisitions Corp. to create a publicly traded technology-enabled care platform providing value-based care and chronic disease management to seniors.

DLA Piper advises Harrison Street on US\$1.6 billion medical office and senior housing transactions

17 June 2021

DLA Piper advised Harrison Street on an integrated series of transactions through which Harrison Street agreed to purchase 24 senior housing assets and sell 14 medical office properties across eight states over numerous months for a total transaction value of approximately US\$1.6 billion.

DLA Piper lawyers and practices ranked in latest Chambers edition

1 June 2021

DLA Piper today announced that the firm received 216 lawyer rankings and 94 firm rankings in *Chambers USA's* 2021 guide.

Tracy Weir joins DLA Piper's Litigation and Regulatory practice and Healthcare sector in Washington, DC

17 May 2021

DLA Piper announced today that Tracy Weir has joined the firm's Litigation and Regulatory practice and Healthcare sector as a partner based in Washington, DC.

DLA Piper advises Denali Growth Partners in closing of US\$203 million growth equity fund

30 March 2021

DLA Piper represented Denali Growth Partners in the close of its US\$203 million inaugural fund, Denali Growth Partners Fund I, L.P.

DLA Piper advises ICV Partners in control investments in Total Access Urgent Care and Cherry Tree Dental

25 March 2021

DLA Piper represented ICV Partners, LLC in its control investments in Total Access Urgent Care (TAUC) and Cherry Tree Dental.

DLA Piper advises Truvian Sciences in oversubscribed US\$105 million Series C financing

24 February 2021

DLA Piper represented Truvian Sciences in its recent oversubscribed US\$105 million Series C financing.

DLA Piper advises EQ Health Acquisition Corp. in its upsized US\$220 million initial public offering

11 February 2021

DLA Piper represented EQ Health Acquisition Corp. in its recent upsized initial public offering of 21,999,960 units at a price of \$10 per unit.

DLA Piper advises Sidecar Health in US\$125 million Series C financing

3 February 2021

DLA Piper represented health insurtech company Sidecar Health in its recent US\$125 Series C financing, resulting in its subsequent valuation at US\$1 billion.

DLA Piper advises Unseen Capital Health Fund in US\$30 million investment from Eli Lilly and Company

25 January 2021

DLA Piper represented Unseen Capital Health Fund LP in a recent US\$30 million limited partner investment from global pharmaceutical company Eli Lilly and Company.

DLA Piper advises Stifel in Tastemaker Acquisition Corp.'s US\$276 million IPO and advises Stifel and Nomura in

OCA Acquisition Corp.'s US\$149.5 million IPO

21 January 2021

DLA Piper represented Stifel as sole book-running manager of the US\$276 million initial public offering by Tastemaker Acquisition Corp., a special purpose acquisition company (SPAC) focused on the restaurant, hospitality, and related technology and service sectors globally.

The *Financial Times* ranks DLA Piper second Most Innovative and second Most Digital law firm in 2020 North America Innovative Lawyers report

16 December 2020

DLA Piper is pleased to announce it was ranked second by the *Financial Times* for both the Most Innovative and Most Digital law firm in the FT North America Innovative Lawyers 2020 report.

DLA Piper shortlisted by the *Financial Times* for five FT North America Innovative Lawyers awards

8 December 2020

DLA Piper is pleased to announce it has been shortlisted by the *Financial Times* for five FT North America Innovative Lawyers 2020 awards.

DLA Piper advises Abry Partners in its investment in Benefit Recovery Group

23 October 2020

DLA Piper represented private equity investment firm Abry Partners in its strategic investment in Benefit Recovery Group (BRG), a leading provider of healthcare subrogation services.

Enforcement and Compliance

DLA Piper's Healthcare Enforcement and Compliance practice is a multi-disciplinary team that provides services in the areas of **prevention, compliance and advocacy** to members of the Healthcare community.

PREVENTION

- Providing "ready reference" compliance advice
- Assessing, building and strengthening compliance programs
- Anticipating and preventing legal and reputational risks
- Performing due diligence in healthcare transactions

COMPLIANCE

- Clarifying applicable standards, often in novel or esoteric areas
- Achieving compliance when it is in question
- Investigating potential non-compliance with applicable standards
- Taking appropriate remedial measures

ADVOCACY

- Defending lawsuits and investigations initiated by state and federal regulators and enforcers
- Defending whistleblower cases
- Responding rapidly when there is a government request for information
- Advocating in Recovery Audit Contractor (RAC), Medicare, Medicaid and payer audits
- Assisting with the defense, appeals and litigation of denied claims for reimbursement

OUR TEAM

We have lawyers across the United States and around the globe who have dedicated their careers to helping clients establish and maintain legal and regulatory compliance, and defend against government enforcement actions. Ten of our lawyers are Certified in Compliance, which we believe is more than any other law firm in the world.

OUR APPROACH

As we serve members of the healthcare industry in the current challenging environment, we provide value by using:

- Diverse teams that are best suited for the specific issue
- Diligent and focused assessments
- Rigorous, collaborative planning and execution
- Techniques to diminish internal client disruption and distraction from core activities
- Advice that provides clarity in the ever-changing healthcare climate
- Fresh perspectives and innovative strategies

WHAT WE DO

- Assess and enhance compliance program effectiveness
- Focus on industry-provider relationships and transparency
- Emphasize compliant physician-hospital relationships
- Assist with troublesome Medicaid issues, which are more prevalent in the post-reform environment
- Perform compliance due diligence in transactions
- Defend against regulatory enforcement and whistleblower actions and investigations
- Provide comprehensive privacy and security counseling
- Handle claims audits and reimbursement disputes

OUR CLIENTS

- Hospitals and health systems
- Academic medical centers
- Hospice, durable medical equipment, home health and long-term-care providers
- Physician groups
- Allied healthcare professionals
- Ancillary service providers

THE KINDS OF MATTERS WE HANDLE

- Government investigations and False Claims Act cases
- Internal investigations
- Whistleblower cases
- Stark Law and Anti-Kickback concerns
- Medicare and Medicaid issues
- Reimbursement disputes
- Exclusion proceedings

- Voluntary disclosures
- RAC and other government audits
- Privacy and security
- Drug Enforcement Agency (DEA) issues
- Clinical trials

OUR EXPERIENCES

A sampling of clients and matters:

- Hospitals, healthcare providers and physician groups in several investigations by the Department of Health and Human Services- Office of Inspector General (OIG) and the Department of Justice
- Health systems in the DOJ's national Implantable Cardioverter Defibrillator (ICD) investigation.
- Defense of whistleblower suits brought by disgruntled third parties
- Defense of allegations that hospitals' services were medically unnecessary and therefore not reimbursable
- A hospital in a dispute with former third-party billing and management companies related to alleged improprieties by those companies
- The operator of long-term-care facilities in parallel state and federal investigations
- A large academic medical center in government investigations relating to billings to federal healthcare programs
- Various clients in False Claims Act lawsuits alleging false billings to federal healthcare programs
- Allied health providers embroiled in parallel state and federal administrative, civil and criminal investigations into alleged billing for medically unnecessary services
- A public hospital regarding its voluntary disclosure of potential billing deficiencies
- A health system in a putative class action brought by former patients and an employee alleging improper billings to commercial payers
- A pharmacy provider in an investigation by the DOJ and the DEA
- Hospital systems in defending against RAC and other third-party payer audits
- A major children's hospital in regulatory, reimbursement and fraud and abuse counseling. The hospital ultimately refined its compliance program
- Stark and Anti-Kickback counseling for health providers

KEY CONTACT



Joshua Kaye
Chair, US Healthcare Sector